Premium
Hepatitis B third‐generation vaccines: improved response and conventional vaccine non‐response – third generation pre‐S/S vaccines overcome non‐response
Author(s) -
Zuckerman J. N.
Publication year - 1998
Publication title -
journal of viral hepatitis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.329
H-Index - 100
eISSN - 1365-2893
pISSN - 1352-0504
DOI - 10.1046/j.1365-2893.1998.0050s2013.x
Subject(s) - reactogenicity , immunogenicity , medicine , seroconversion , hepatitis b vaccine , vaccination , virology , antibody response , hepatitis a vaccine , immunology , immune system , antibody , hepatitis b virus , virus , hbsag
A new triple‐S containing recombinant hepatitis B vaccine was evaluated in terms of immunogenicity and reactogenicity in a cohort of healthy healthcare professionals who were persistent non‐responders to the currently licensed hepatitis B vaccines. One hundred subjects were allocated randomly to receive two doses of 5, 10, 20 or 40 μg of a new hepatitis B vaccine 2 months apart. The overall seroconversion rate was 70% with a single dose of 20 μg of the vaccine being as effective as two doses of either 20 μg or 40 μg of the vaccine formulation in terms of seroconversion, seroprotection and geometric mean titres.